Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe

Economic evaluation of 65 cancer drugs approved 2009-19 found launch prices were much higher in the US than in similar high-income European countries, and prices frequently increased faster than inflation. Price changes were not associated with clinical benefit in any country.

JAMA Oncology